Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

New Jersey Resources (NJR) Cash & Equivalents (2016 - 2025)

New Jersey Resources' Cash & Equivalents history spans 17 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 27.57% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 27.57%, while the annual FY2025 figure was $591000.0, 41.89% down from the prior year.
  • Cash & Equivalents reached $2.4 million in Q4 2025 per NJR's latest filing, up from $591000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $83.7 million in Q1 2025 to a low of $511000.0 in Q2 2023.
  • Average Cash & Equivalents over 5 years is $13.1 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 98.15% in 2023, then surged 4283.37% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $1.3 million in 2021, then skyrocketed by 91.18% to $2.4 million in 2022, then increased by 13.79% to $2.7 million in 2023, then crashed by 30.34% to $1.9 million in 2024, then increased by 27.57% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for NJR's Cash & Equivalents are $2.4 million (Q4 2025), $591000.0 (Q3 2025), and $931000.0 (Q2 2025).